期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 19, 期 11, 页码 1355-1366出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2010.520701
关键词
Akt; biomarker; GSK2141795; MK-2206; PBI-05204; perifosine; RX-0201
资金
- NIH [K12 2K12CA001727-16A1]
- California Breast Cancer Research Program [CBCRP 15IB-0140]
- Amgen
- Novartis
- GSK
- Pfizer
- Argos
- Antisoma
- Phase One Foundation
- Baumel Family
- OSI Pharmaceuticals
Importance of the field: The evolution of targeted therapies is dependent upon identification of cellular moieties that can be pharmacologically modulated. As one such example, the serine-threonine kinase Akt was identified nearly two decades ago. Since then, its role in mediating multiple signaling cascades (ultimately leading to cell growth and proliferation) has since been identified. More recently, several agents have been developed that antagonize Akt - these agents are in various stages of clinical testing. Areas covered in this review: Herein, we outline development of several promising Akt inhibitors, including perifosine, MK-2206, RX-0201, PBI-05204, GSK2141795 and others. What the reader will gain: The reader will gain insight into the current pipeline of Akt inhibitors, and the degree to which these agents have been examined both clinically and preclinically. Take home message: With an emerging pipeline of agents targeting Akt, it will be critical to decipher which amongst them holds the greatest promise. Herein, we explore this drug pipeline and provide strategies for determining the future clinical application of these agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据